Scholarlink

<p>Neuropeptide Y (NPY) is a multifunctional peptide with neuroprotective properties, but its therapeutic use in the retina and optic nerve may be limited by vasoconstrictive effects mediated through Y1 receptor activation. This study evaluated the vascular effects of full-length NPY (1–36) and its N-terminally truncated analog, NPY (3–36), in the mouse retina. Retinal vascular responses were assessed using fluorescein angiography (FFA) after intravitreal administration of different NPY analogs. NPY (1–36) caused transient vasoconstriction via Y1 receptor-mediated calmodulin and pMLC activation. In contrast, NPY (3–36) selectively activates Y2 and Y5 receptors without inducing vasoconstrictive effects. Furthermore, NPY (3–36) through receptor activation preserved retinal ganglion cell density, axonal integrity, and inner retinal function while reducing astrocytic and microglial activation under elevated intraocular pressure. These findings suggest that NPY (3–36) could be a safer therapeutic candidate for glaucoma, highlighting the critical role of receptor-specific modulation to enhance neuroprotection without causing adverse vascular complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selective Receptor Modulation by Truncated Neuropeptide Y (3–36) Dissociates Vasoconstriction from Neuroprotection in Experimental Glaucoma

  • 期刊论文

  • 发表日期：

    2025年12月29日

查看全文
  • Viswanthram Palanivel,
  • Devaraj Basavarajappa,
  • Akanksha Salkar,
  • András M. Komáromy,
  • Ole Tietz,
  • Taslima Akter Eva,
  • Nitin Chitranshi,
  • Mehdi Mirzaei,
  • Veer Gupta,
  • Yuyi You,
  • Stuart L. Graham,
  • Vivek Gupta

摘要

Neuropeptide Y (NPY) is a multifunctional peptide with neuroprotective properties, but its therapeutic use in the retina and optic nerve may be limited by vasoconstrictive effects mediated through Y1 receptor activation. This study evaluated the vascular effects of full-length NPY (1–36) and its N-terminally truncated analog, NPY (3–36), in the mouse retina. Retinal vascular responses were assessed using fluorescein angiography (FFA) after intravitreal administration of different NPY analogs. NPY (1–36) caused transient vasoconstriction via Y1 receptor-mediated calmodulin and pMLC activation. In contrast, NPY (3–36) selectively activates Y2 and Y5 receptors without inducing vasoconstrictive effects. Furthermore, NPY (3–36) through receptor activation preserved retinal ganglion cell density, axonal integrity, and inner retinal function while reducing astrocytic and microglial activation under elevated intraocular pressure. These findings suggest that NPY (3–36) could be a safer therapeutic candidate for glaucoma, highlighting the critical role of receptor-specific modulation to enhance neuroprotection without causing adverse vascular complications.